TRAILHEAD BIOSYSTEMS, INC.
BEACHWOOD, OH · CIK 0001814509 · Biotech · Private
Serum-free, chemically defined cell culture media formulations for human T lymphocyte and CD34+ hematopoietic stem cell expansion
trailbio.com →- Grants
- $147K
- 1 award
- Sector median: 1
- Raised
- $30M
- 5 Form D · Jul 2024
- 27 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 2 granted · 38 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Generation of serum- free media for expansion of human T lymphocytes and CD34+ HSCs using High Dimensional Design of Experiments (HD-DoE) | $146,531 | |
| Private capital raised | Form D · SEC | $100,000 | |
| Private capital raised | Form D · SEC | $6,575,741 | |
| Private capital raised | Form D · SEC | $9,999,999 | |
| Private capital raised | Form D · SEC | $3,000,000 | |
| Private capital raised | Form D · SEC | $10,000,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1442 | Centaurus Therapeutics, Inc. | — | $2.0M |
| 1443 | ACUREX THERAPEUTICS CORPORATION | — | — |
| 1444 | Werewolf Therapeutics, Inc. | — | $104M |
| 1445 | TRAILHEAD BIOSYSTEMS, INC. | — | $30M |
| 1446 | Saliogen Therapeutics, Inc. | — | $94M |
| 1447 | BRAINSTORM THERAPEUTICS, INC. | — | — |
| 1448 | Peptilogics | — | $41M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Houman HemmatiDirector
- Wolfgang HofmannDirector
- Jan JensenDirector · Executive Officer
- Michael KaufmanDirector
- David LlewellynDirector · Executive Officer
- Craig NemiroffDirector · Executive Officer
- Magnus PerssonDirector
- Joshua SnowExecutive Officer
- Div TrivediExecutive Officer
- Divya TrivediDirector · Executive Officer
Patents
- Methods And Compositions For Generating Oligodendrocyte Progenitor Cellsgranted
- Methods And Compositions For Generating Hepatocytesapplication
- Methods And Compositions For Generating Hematopoietic Progenitor Cellsapplication
- Methods And Compositions For Generating Oligodendrocyte Progenitor Cellsapplication
- Methods And Compositions For Generating Vascular Leptomeningeal Cellsapplication
- Methods And Compositions For Generating Oligodendrocyte Progenitor Cellsgranted
- Methods To Improve Enduring Hematopoietic Stem Cell Transplantationapplication
- Methods And Compositions For Generating Somatostatin+ Interneurons From Human Forebrain Neural Progenitor Cellsapplication
- Methods And Compositions For Maintaining Aggregate Stability And Pluripotency Of Stem Cellsapplication
- Methods And Compositions For Generating Oligodendrocyte Progenitor Cellsapplication
- Methods And Compositions For Generating Oligodendrocyte Progenitor Cellsapplication
- Compositions And Methods For Small Molecule Based Expansion Of Pluripotent Stem Cellsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.